e-Drug3D

2178

DOXRIBTIMINE


INN
DOXRIBTIMINE

cas 50-89-5
CLASS

METABOLISM
PYRIMIDINE NUCLEOSIDE
TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D)
INCORPORATED INTO SKELETAL MUSCLE MITOCHONDRIAL DEOXYRIBONUCLEIC ACID (DNA)

ROUTE (list)

ORAL

ATC code

A16AX29

PK parameters

Tmax 4 HOUR
PPB 10 PERCENT
t1/2 5 HOUR

Target

TARGET DNA

DrugCentral

-

Download SDF file Thymidine

Formula:
C10H14N2O5

Calculated chemical properties:

MW 242.23
NB_atoms 17
XLogP -1.51
PSA 100.68
NB_HD 3
NB_HA 7
fsp3 0.60
Lipinski(0=no;1=yes) 1

FDA
NDA 219792 (label) INN (DOXECITINE ; DOXRIBTIMINE) KYGEVVI (UCB INC) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL